NEAL ANTHONY SCOTT, M.D., Ph.D.
Curriculum Vitae
PROFESSIONAL ADDRESS:
Peninsula Cardiovascular, Inc.
2490 Hospital Drive, Suite 212
Mountain View, CA 94040
Telephone: (650) 962-4460
EDUCATION:
1971-1975
B.S., Stanford University, Stanford, CA (Chemistry)
1975-1982
Ph.D., Massachusetts Institute of Technology, Cambridge, MA
(Neural and Endocrine Regulation)
1975-1982
M.D., Harvard Medical School, Boston, MA
POSTGRADUATE TRAINING:
1982-1983
1983-1985
1985-1989
1986-1989
1989-1990
Intern, Internal Medicine, Univ. of California, San Diego
Resident, Internal Medicine, Univ. of California, San Diego
Fellow in Cardiology, Stanford University, Stanford, CA
Postdoctoral Research Fellow, UC San Diego
Fellow in Coronary Interventions, Emory University Medical Center,
Atlanta, GA
WORK HISTORY:
2006-
Cardiologist in Private Practice
2000-2006
Founder, Vice-President, Medical Director, Medluminal Systems, Inc.
1998-2001
Associate Professor, Emory University School of Medicine, Atlanta, GA
1990-1998
Assistant Professor, Emory University School of Medicine, Atlanta, GA
ACADEMIC APPOINTMENTS:
Primary Appointments:
1
1998-2001
1990-1998
Associate Professor, Emory University School of Medicine, Atlanta, GA
Assistant Professor, Emory University School of Medicine, Atlanta, GA
Secondary Appointments:
1986 – 1989
1990 - 2001
Clinical Instructor, Stanford University, Stanford, CA
Collaborative Scientist, Yerkes Regional Primate Center, Atlanta, GA
CLINICAL APPOINTMENTS:
1986 – 1989
1987 – 1989
1990 – 2001
1990 – 2001
1990 – 1994
1990 – 1994
1994 - 2001
2002 2005 2006 2009 -
Instructor, Dept of Surgery (Emergency Dept. and Life Flight Attending),
Stanford University
Life Flight Attending, UC San Diego
Cardiology Attending, Emory University Hospital, Atlanta, GA
Cardiology and Internal Medicine Attending, Grady Memorial Hospital,
Atlanta, GA
Cardiology Attending, Atlanta Veterans Administration Hospital, Atlanta,
GA
Member, The Emory Clinic, Atlanta, GA
Senior Member, The Emory Clinic, Atlanta, GA
Cardiologist, El Camino Hospital, Mountain View, CA
Cardiologist, O’Connor Hospital, San Jose, CA
Cardiology Attending, Palo Alto Veterans Administration Hospital, Palo
Alto, CA
Cardiology Attending, Stanford University Medical Center, Stanford, CA
LICENSURES:
1989 - 2003
1984 - 1990
2002 -
Licensed Physician, State of Georgia, #032048 (expired)
Licensed Physician, State of California, #G52828
Licensed Physician, State of California, #G52828
BOARD CERTIFICATIONS:
2010
1999
1989
1985
1984
Interventional Cardiology, American Board of Internal Medicine,
Certificate # 105904 (Re-certification)
Interventional Cardiology, American Board of Internal Medicine,
Certificate # 105904
Cardiovascular Diseases, American Board of Internal Medicine,
Certificate # 105904
Internal Medicine, American Board of Internal Medicine, Certificate #
105904
Diplomate, National Board of Medical Examiners, Certificate # 211275
2
COMMITTEE MEMBERSHIPS:
National:
1995 - 2000
Data Safety and Monitoring Committee (NIH): The SHOCK Trial
Regional and State:
1992 - 1995
1993 - 2000
1998 - 2000
Research Peer Review Committee, American Heart Assoc,
Georgia Affiliate
Board of Directors, American Heart Association, (DeKalb County
Branch)
Medical Director, American Heart Association, (Dekalb County
Branch)
Institutional:
1993 - 2000
1997- 1998
Emory Medical School Admissions Committee (Associate
Member),
Human Resources Committee (Emory Clinic)
INDUSTRY EXPERIENCE:
Founder, XRT Corporation, St. Paul, MN, 1994
Medical Director, XRT Corporation, 1996 – 1998
XRT developed a catheter with an X-ray generator at its tip for use in
coronary and peripheral arteries. The company was acquired by
Medtronic Inc. in 2000
Founder, Medluminal Systems, Inc., Palo Alto, CA 2000
Vice President and Medical Director, Medluminal Systems, 2000-2006
Medluminal Systems developed drug delivery catheters for coronary and
peripheral vascular indications. The intellectual property for these devices
was acquired by Boston Scientific Corp. in 2006.
Consultant, CardioMind, Inc., Sunnyvale, CA 2005 - 2010
CardioMind has developed a guidewire-based stent delivery system for
coronary and peripheral indications. CardioMind was acquired by
Biosensors International in 2010.
3
MANUSCRIPT REVIEWER:
Ad Hoc Reviewer:
Circulation
Journal of the American College of Cardiology
American Journal of Cardiology
Catheterization and Cardiovascular Interventions
Coronary Artery Disease
American Heart Journal
American Journal of Medical Sciences
AWARDS AND HONORS
1992-1994
1987-1989
1982
1979-1981
Robert Wood Johnson Foundation Fellowship
Robert Wood Johnson Foundation Fellowship
Kaiser Merit Fellowship (Harvard Medical School)
Whitaker Health Sciences Fellowship (Massachusetts Institute of
Technology)
Sandoz Foundation Fellowship (Massachusetts Institute of Technology)
SOCIETY MEMBERSHIPS:
1993 1993 - 2000
1991 1983 - 2000
Fellow, American College of Cardiology
Member, Society for Cardiac Angiography and Interventions
Member, American Heart Association
Member, American Federation of Clinical Research
ORGANIZATION OF NATIONAL OR INTERNATIONAL CONFERENCES:
SESSIONS AS CHAIRMAN:
1991
American Heart Association Scientific Sessions; "Coronary
Atherectomy".
1993
American College of Cardiology; "Restenosis Animal Models".
1994
American College of Cardiology; "Local Delivery" and "Basic
Mechanisms in Restenosis".
1995
American College of Cardiology; "Local Intracoronary Delivery".
4
1995
American Heart Association Scientific Sessions; “Intracoronary
Ultrasound and Doppler”.
1998
American College of Cardiology; “Late-breaking Clinical Trials”.
1998
American Heart Association Scientific Sessions; “Intracoronary
Radiation”.
PATENTS:
ISSUED:
Boublik JH, Rivier JEF, Brown MR, Scott NA: NPY Peptide Analogs. U.S.
Patent Number: 5,026,685. Issued: June 25, 1991.
Boublik JH, Rivier JEF, Brown MR, Scott NA: NPY Peptide Analogs. U.S.
Patent Number: 5,328,899. Issued: Jul. 12, 1994
Scott NA, Hanson SR, King SB III, Harker LA. Stent sheath for local drug
delivery. U.S. Patent Number 5,383,928. Issued: January 24, 1995.
Hanson SR, Scott NA, King SB III, Harker LA. A device for local drug delivery
and methods for using the same. U.S. Patent Number 5,523,092. Issued: June 4,
1996.
Hanson SR, Scott NA, King SB III, Harker LA. A device for local drug delivery
and methods for using the same. U.S. Patent Number 5,709,874. Issued: January
20, 1998.
Hanson SR, Scott NA, Markou C, King SB III. Device and method for nonocclusive localized drug delivery. U.S. Patent Number 5,985,307. Issued:
November 16, 1999.
Waksman R, King SB, Scott NA. Endovascular support device and method of
use. U. S. Patent Number 6,355,055. Issued: March 12, 2002.
Hampikian JM, Scott NA. Radioactive coating solutions, methods and substrates.
US Patent Number 6,475,644 B1. Issued: November 5, 2002
Scott NA, Segal J. Mechanical apparatus and method for dilating and delivering
a therapeutic agent at a site of treatment. US Patent Number 7,292,885. Issued:
November 6, 2007.
5
Segal J, Scott NA. Mechanical apparatus and method for dilating and delivering a
therapeutic agent to a site of treatment. US Patent Number 7,488,313. Issued:
February 10, 2009
Segal J, Scott NA. Mechanical apparatus and method for dilating and delivering a
therapeutic agent to a site of treatment. US Patent Number 7,488,314. Issued:
February 10, 2009
Scott NA, Segal J, Shih LB, Harris S, Burkoth T. Polymer coated device for
electrically mediated drug delivery. US Patent Number 7,517,342. Issued: April
14, 2009.
Scott NA, Segal J. Mechanical apparatus and method for dilating and delivering a
therapeutic agent to a site of treatment. US Patent Number 7,519,418. Issued:
April 14, 2009.
PENDING (published):
Scott NA, King SB III. Catheter and method for ostial stent placement (European
Union Patent Application).
Scott NA, Hampikian JM. Bachytherapy device and method of use. US Patent
Application # 20030092957.
Segal J, Hampikian JM, Scott NA. Device and method for dilating and
irradiating a vascular segment or body passageway. US Patent Application #
20020077520.
Segal J, Scott NA. Mechanical apparatus and method for dilating and delivering
a therapeutic agent at a site of treatment. US Patent Application # 20030100886.
Scott NA, Segal J. Mechanical apparatus and method for dilating and delivering
a therapeutic agent at a site of treatment. US Patent Application # 20030100887.
Scott NA, Segal J. Charged liposomes or micelles with encapsulated medical
compounds. US Patent Application # 20040034336.
Scott NA, Segal J, Burkoth T, Harris S. High concentration medicament and
polymer coated device for passive diffusional drug delivery. US Patent
Application # 2005/0159704.
6
Segal J, Scott NA. Mechanical apparatus and method for dilating and delivering a
therapeutic agent to a site of treatment. US Patent Application #2005/0054978.
GRANT SUPPORT:
NIH Sponsored Grants:
Small Business Innovative Research (SBIR) Award): “Prevention of Restenosis
with a Novel Radiation Catheter” 8/2001 – 3/2002 (1R43 CA88636-01A1;
Principal Investigator: N.A. Scott)
5 RO1 HL47838 NIH/NHLBI: (co-investigator); (Principal Investigator: J.N.
Wilcox) “Thrombosis and Vascular Lesion Formation”, 9/91 - 7/96
1 RO1 HL49743 NIH/NHLBI: (co-investigator); (Principal Investigator: J.N.
Wilcox) “Biological Mediators of Atherogenesis in Black Americans”, 9/92 9/96
Other:
Georgia Research Alliance (Faculty Research Commercialization Program): “A
Catheter for Intracoronary Radiation” 7/98 – 6/99; (Principal Investigator: N.A.
Scott)
Georgia AHA Grant-in-Aid: (Principal Investigator: N.A. Scott) “Restenosis:
Mechanisms and Management”, 7/96 - 6/98
7
MANUSCRIPTS:
1.
Scott NA, DeSilva RA, Lown B, Wurtman RJ. Tyrosine administration decreases
vulnerability to ventricular fibrillation in the normal canine heart. Science
211:727-729, 1981.
2.
Reinstein DK, Lehnert H, Scott NA, Wurtman RJ. Tyrosine prevents behavioral
and neurochemical correlates of an acute stress in rats. Life Sciences 34:22252231, 1984.
3.
Maisel AS, Scott NA, Gilpin E, Ahnve S, LeWinter M, Henning H, Collins D,
Ross J. Complex ventricular arrhythmias in Qwave versus non-Q-wave
myocardial infarction. Circulation 72:963-970, 1985.
4.
Scott NA, Webb V, Boublik JH, Rivier J, Brown M. The cardiovascular actions
of centrally administered Neuropeptide Y. Regulatory Peptides 25: 247258,1989.
5.
Boublik JH, Scott NA, Brown MR, Rivier J. Structure-activity relationships of
D-substituted and N-terminally modified analogs and C- and N- terminal
fragments of neuropeptide Y. J Med Chem 32:597-601, 1989.
6.
Maisel AS, Scott NA, Motulsky HJ, Ziegler M, Brown MR. Elevation of
Neuropeptide Y in congestive heart failure. Am J Med 86:43-48, 1989.
7.
Boublik JH, Scott NA, Taulane J, Goodman M, Brown M, Rivier J. Neuropeptide
Y and Neuropeptide Y 18-36; structural and biological characterization. Intl J
Pept Prot Res 33:11-15,1989.
8.
Scott NA, Michel MC, Boublik JH, Rivier JE, Motomura S, Crum RL, Landon
M, Brown MR. Distinction of NPY receptors in vitro and in vivo II. Differential
effects of NPY and NPY-(18-36). Am J Physiol 259:H174-H180, 1990.
9.
Boublik JH, Spicer MA, Scott NA, Brown MR, Rivier JE. Biologically active
Neuropeptide Y analogs. Ann NY Acad Sci 611:27-34,1990.
10.
Allen RA, Boublik J, Hauger RL, Scott N, Rivier J, Brown MR. Neuropeptide Y
radioimmunoassay: characterization and application. Clinical and Experimental
Pharmacology and Physiology 18: 825-833, 1991.
11.
Feinstein RD, Boublik JH, Kirby D, Spicer MA, Craig AG, Malewicz K, Scott
NA, Brown MR, Rivier JE. Structural requirements for Neuropeptide Y18-36
evoked hypotension: a systematic study. J Med Chem 35: 2836-2843, 1992.
8
12.
Segal J, Kern MJ, Scott NA, King SB 3rd, Doucette JW, Heuser RR, Offili E,
Siegel R. Alterations of phasic coronary artery flow velocity in humans during
percutaneous coronary angioplasty. J Am Coll Cardiol 20: 276-286, 1992.
13.
Scott NA, King SB 3rd. Coronary stents. Coronary Artery Dis 3:901-907, 1992.
14.
Scott NA, Weintraub WS, Carlin SF, Tao X, Douglas JS Jr, Lembo NJ, King SB
3rd. Recent changes in the management of acute closure during coronary
angioplasty. Am J Cardiol 71:1159-1163, 1993.
15.
Vyavahare N, Scott NA, Hanson SR, Kohn J. In vitro and in vivo evaluation of
the site specific administration of d-phenylalanyl-l-prolyl-l-arginyl chloromethyl
ketone (PPACK) - a powerful thrombin inhibitor. Journal of Controlled Release
27:165-173,1993.
16.
Scott NA, Kelsey SF, Detre K, Cowley MJ, King SB 3rd, and the NHLBI PTCA
Registry Investigators. Percutaneous Transluminal Coronary Angioplasty in
African-Americans: an analysis of the National Heart, Lung and Blood Institute
PTCA Registry. Amer J Cardiol 73:1141-1146, 1994.
17.
Scott NA, Pettigrew RI. Absence of movement of coronary stents after
placement in a magnetic resonance imaging field. Amer J Cardiol 73:900-901,
1994.
18.
Nunes GL, Hanson SR, King SB 3rd, Sahatjian RA, Scott NA. Local delivery of
an antithrombin with a hydrogel-coated PTCA balloon catheter inhibits plateletdependent thrombosis. J Amer Coll Cardiol 23: 1578-1583, 1994.
19.
Waksman R, Ghazzal ZMB, Scott NA, Douglas JS Jr, King SB 3rd. Efficacy and
safety of using perfusion dilatation catheter as initial balloon in coronary
angioplasty. Catheter Cardiovasc Diagnosis 32:319-322, 1994.
20.
Scott NA, Nunes GL, King SB 3rd, Harker LA, Hanson SR. Local delivery of an
antithrombin inhibits platelet-dependent thrombosis. Circulation 90:1951-1955,
1994.
21.
Robinson KA, Candal FJ, Scott NA, Ades EW. Seeding of vascular grafts with
an immortalized human dermal microvascular endothelial cell line. Angiology
46:107-13, 1995.
22.
Waksman R, Douglas JS Jr, Scott NA, Ghazzal ZM. Yee-Peterson J, King
SB 3rd. Distal embolization is common after directional atherectomy in coronary
arteries and saphenous vein grafts. Amer Heart Journal 129:430-5, 1995.
9
23.
Scott NA, Thomas CN, Nunes GL, Robinson KA, Rowland SM, Juman I, Harker
LA, King SB 3rd, Hanson SR. A comparison of the thrombogenicity of stainless
steel and tantalum coronary stents. Amer Heart Journal 129:866-72, 1995.
24.
Scott NA, Candal FJ, Robinson KA, Ades EW. Seeding of intracoronary stents
with immortalized human microvascular endothelial cells. Amer Heart Journal
129:860-66, 1995.
25.
Scott NA. Current status and potential applications of drug delivery balloon
catheters. J Interventional Cardiology 8:406-419, 1995.
26.
Scott NA, McManamon R, Strobert E, Cipolla G, Tarazona N, Swenson RB. Invivo diagnosis of coronary artery disease in a gorilla. J Zoo and Wildlife Med
26:139-143, 1995.
27.
Nunes GL, Thomas CN, Hanson SR, Barry JJ, King SB 3rd, Scott NA. Local
delivery of heparin via a hydrogel-coated PTCA balloon catheter inhibits plateletdependent thrombosis. Circulation 92:1697-1700, 1995.
28.
Thomas CN, Weintraub WS, Shen Y, Ghazzal ZMB, Douglas JS Jr, King SB 3rd,
Scott NA. Bailout coronary stenting in patients with a recent myocardial
infarction. Amer J Cardiol 77: 653-655, 1996.
29.
Waksman R, Scott NA, Ghazzal ZMB, Mays R, Frerichs FA, Petersen JY, King
SB 3rd. A randomized comparison of flexible versus non-flexible femoral
sheaths on patient comfort after angioplasty. Amer Heart Journal 131: 10761078, 1996.
30.
Scott NA, Cipolla GD, Ross CE, Dunn B, Martin F, Simonet L, Wilcox JN.
Potential role of the adventitia in vascular lesion formation after balloon
overstretch injury of porcine coronary arteries. Circulation 93: 2178-2187, 1996.
31.
Wilcox JN, Scott NA. Potential role of the adventitia in arteritis and
atherosclerosis. International J Cardiol 54: (Suppl.) S21-S35, 1996.
32.
Thomas CN, Robinson KA, Cipolla GL, King SB 3rd, Scott NA. Local
intracoronary delivery of heparin with a microporous balloon catheter. Amer
Heart Journal 132: 969-972, 1996.
33.
Wilcox JN, Waksman R, King SB 3rd, Scott NA. The role of the adventitia in the
arterial response to angioplasty. International Journal of Radiation Oncology,
Biology, Physics 36: 789- 796, 1996.
34.
Jones SA, Leclerc H, Chatzimavroudis GP, Kim YH, Scott NA, Yoganathan AP.
The influence of acoustic impedance mismatch on post-stenotic pulsed-doppler
10
ultrasound measurements in a coronary artery model. Ultrasound in Medicine &
Biology 22: 623-34, 1996.
35.
Wilcox JN, Cipolla GD, Martin FH, Simonet L, Dunn B, Ross CE, Scott NA.
Contribution of adventitial myofibroblasts to vascular remodeling and lesion
formation after experimental angioplasty in pig coronary arteries. Ann NY Acad
Sci 811:437-47, 1997.
36.
De Leon H, Scott NA, Martin F, Simonet L, Bernstein KE, Wilcox JN.
Expression of nonmuscle myosin heavy chain-B isoform in the vessel wall of
porcine coronary arteries after balloon angioplasty. Circulation Research 80:514519, 1997.
37.
Waksman R, Rodriguez JC, Robinson KA, Cipolla GD, Crocker IR, Scott NA,
King SB 3rd, Wilcox JN. Effect of intravascular irradiation on cell proliferation,
apoptosis and vascular remodeling after balloon overstretch injury of porcine
coronary arteries. Circulation 96:1944-1952, 1997.
38.
Waksman R, Weintraub WS, Ghazzal ZMB, Scott NA, Shen Y, King SB 3rd,
Douglas JS Jr. Acute and long-term outcome of narrowed saphenous vein bypass
graft. A comparison of treatment with Palmaz-Schatz stent, directional coronary
atherectomy and balloon angioplasty. Amer Heart J 134(2 Pt 1):274-81, 1997.
39.
Viel K, Cui J, Thomas CN, Nunes GL, Cipolla G, King SB 3rd, Scott NA.
Inhibition of platelet deposition with local delivery of heparin using a double
balloon catheter. Thrombosis Research 88:147-157, 1997.
40.
Scott NA. Hyperlipidemia in African-Americans. ABC Digest of Urban
Cardiology 4:17-22, 1997.
41.
Scott NA, Wilcox JN. Role of the adventitial vasculature in resteonsis: a new
view of an old problem. J Amer Coll Cardiol 32 (7): 2080, 1998.
42.
Levy D, Merz CNB, Cody RJ, Fouad-Tarazi FM, Francis CK, Pfeffer MA, Scott
NA, Swan HJC, Taylor MP, Weinberger MH. Hypertension detection, treatment
and control. A call to action for cardiovascular specialists. J Amer Coll Cardiol
34:1360-1361, 1999.
43.
Scott NA. The soft x-ray catheter system. Current Interventional Cardiology
Reports 1:48-50, 1999
44.
Scott NA, Crocker IR, Yin QQ, Sorescu D, Wilcox JN, Griendling KK.
Inhibition of vascular cell growth by x-ray irradiation: comparison with gamma
radiation and mechanism of action. Inter J Radiation Oncology, Biology and
Physics 50:485-493, 2001.
11
45.
Garas SM, Huber P, Scott NA. Overview of therapeutics for prevention of
restenosis after coronary interventions. Pharmacology and Therapeutics 92 (23):165-78, 2001.
46.
Okamoto E, Couse T, De Leon H, Vinten-Johansen J, Goodman RB, Scott NA,
Wilcox JN. Perivascular inflammation after balloon angioplasty of porcine
coronary arteries. Circulation 104: 2228-35, 2001.
47.
Scott NA. Restenosis following implantation of bare metal coronary stents:
pathophysiology and pathways involved in the vascular response to injury
Advanced Drug Delivery Reviews 3: 358-376, 2006.
MONOGRAPHS:
Scott NA, editor. Cardiovascular Disorders in African Americans, Physicians
Press, Birmingham, MI, 1997.
CHAPTERS:
1.
Brown MR, Scott NA, Boublik J, Allen RS, Ehlers R, Landon M, Crum R, Ward
D, Bronsther O, Maisel A, Rivier J. Neuropeptide Y: Biological and clinical
studies. In: Neuropeptide Y, V. Mutt, K. Fuxe, T. Hokfelt, J.M. Lundberg (eds),
Raven Press, New York, 1989, pp 321-329.
2.
Boublik JH, Spicer MA, Scott NA, Rivier JE, Brown MR. High dose
Neuropeptide Y elicits biphasic effects on the conscious rat cardiovasculature:
structure-activity studies. In: Maggi M, ed., Horizons in Endocrinology; Raven
Press: New York, 1991; Vol II, pp 229-234.
3.
Scott NA, Gravanis MB. Heart Failure. In: Cardiovascular Disorders:
Pathogenesis and Pathophysiology, Gravanis MB, ed., Mosby - Yearbook, Inc.,
St. Louis, MO, 1993.
4.
Wilcox JN, Waksman R, King SB 3rd, Scott NA. The role of the adventitia in the
arterial response to angioplasty. In: Vascular Brachytherapy, Waksman R, King
SB, Crocker IR, Mould RF, eds. Nucleotron, Veenendaal, Netherlands, 1996.
5.
Scott NA. Photodynamic therapy. In: Vascular Brachytherapy, Waksman R,
King SB, Crocker IR, Mould RF, eds. Nucleotron, Veenendaal, Netherlands,
1996.
6.
Scott NA. Intracoronary Stents. In: Atlas of Heart Diseases, Interventional
Cardiology, Volume XIII, King SB III, Douglas JS Jr, ed., Current Medicine,
Philadelphia, PA; pp 7.1-7.20; 1997.
12
7.
Scott NA. Other Devices. In: Atlas of Heart Diseases, Interventional Cardiology,
Volume XIII, King SB III, Douglas JS Jr, ed., Current Medicine, Philadelphia,
PA; pp 8.1-8.9; 1997.
8.
Scott NA. Hypertension in African Americans. In: Cardiovascular Disorders in
African Americans, Scott NA, editor. Physicians Press, Birmingham, MI, 1997.
9.
Scott NA. Lipid Abnormalities in African Americans. In: Cardiovascular
Disorders in African Americans, Scott NA, editor. Physicians Press,
Birmingham, MI, 1997.
10.
Scott NA. Coronary Disease in African Americans. In: Cardiovascular Disorders
in African Americans, Scott NA, editor. Physicians Press, Birmingham, MI,
1997.
11.
Wilcox JN, Scott NA. Adventitial remodeling associated with post-angioplasty
restenosis. In: Vascular Brachytherapy, 2nd edition, pp21-30 Futura Publishing
Co., Aramonk, NY, 1999.
12.
Wilcox JN, Crocker IR, Scott NA, Robinson KA, King SB III, Waksman R.
Mechanisms by which radiation may prevent restenosis: inhibition of cell
proliferation and vascular remodeling. In: Vascular Brachytherapy, 2nd edition,
pp127-138. Futura Publishing Co., Aramonk, NY, 1999.
13.
Scott NA. Cardiovascular Disorders in African Americans. In: Essentials of
Cardiovascular Medicine, 2nd edition (in press).
14.
Wilcox JN, Scott NA. Adventitial remodeling associated with post-angioplasty
restenosis. In: Vascular Brachytherapy, 3rd edition, Futura Publishing Co.,
Aramonk, NY, pp - , 2002.
15.
Scott NA, Hampikian JM, Segal J. The RadioVascular Systems Catheter. In:
Vascular Brachytherapy, 3rd edition, Futura Publishing Co., Aramonk, NY, pp - ,
2002.
ABSTRACTS (selected):
1.
Scott NA, Verrier RL, Lown B, Wurtman RJ. Mechanisms mediating the
influence of tyrosine on vulnerability to ventricular fibrillation. Clin Res
29:240A, 1981.
2.
Lehnert H, Reinstein DK, Scott NA, Wurtman RJ. Tyrosine prevents tailshockinduced norepinephrine depletion in the locus coeruleus and behavioral
depression in rats. Fed Proc 42:2795A, 1983.
13
3.
Maisel AS, Gilpin EA, Ahnve S, Scott NA, Henning H, Ross J. Complex PVC's
predict 1-year survival in non-Q-wave but not in Q-wave myocardial infarction. J
Am Coll Cardiol 5:521, 1985.
4.
Scott NA, Brown M. Hypotension following intra-artrial administration of a
combination of neuropeptide Y and neuropeptide Y antisera. American Society
of Hypertension Second Annual Meeting, May 17-20, 1987, New York, NY.
5.
Boublik J, Scott N, Brown MR, Rivier J. Neuropeptide Y: Structure-activity
relationships of D-substituted an N-terminally modified analogs. 10th American
Peptide Symposium, May 23-28, 1987, St. Louis, MO.
6.
Scott N, Webb V, Brown MR. Neuropeptide Y: Central nervous system effects
of cardiovascular function. Society for Neuroscience Annual Meeting, November
16-21, 1987, New Orleans, LA.
7.
Scott N, Maisel AS, Motulsky HJ, Brown MR. Elevated Neuropeptide Y levels
in congestive heart failure with a blunted exercise response. Clinical Research 36
(3): 315A, 1988.
8.
Boublik J, Scott N, Brown M, Rivier J. Neuropeptide Y; requirement of an
intact, amidated C- terminus for in vivo hypertensive activity. 8th International
Congress of Endocrinology, 1988.
9.
Crum RL, Allen R, Scott NA, Ehlers R, Ward D, Bronsther O, Hansbrough J,
Rivier J, Boublik J, Maisel A, Rockman H, Nicod P, Brown MR. Neuropeptide Y
(NPY): measurements in human plasma. Endocrine Society Meetings, 1988.
10.
Anderson H, Boublik J, Scott N, Brown M, Hagler A, Rivier J. Computer-assisted
modeling suggests structural similarities between the snake "long" neurotoxins
and neuropeptide Y and related peptides. Second Symp. of The Protein Society,
San Diego, CA Aug. 13-17, 1988.
11.
Scott NA, Boublik JH, Rivier JE, Brown MR. A Neuropeptide Y fragment
decreases cardiac output and mean arterial pressure. Circulation 78: II-223, 1988.
12.
Boublik JH, Scott NA, Brown MR, Rivier JE. Structure-Activity relationships
for substantially truncated, C-terminal fragments of Neuropeptide Y with
hypotensive activity in vivo. 9th Annual conference, Australian Neuroscience
Society, Melbourne, Australia, Feb 6-8 1989.
13.
Boublik J, Anderson H, Scott N, Brown M, Rivier J. Computer analysis suggests
that members of the Neuropeptide Y family and the "long" snake toxins share
structural similarities. 14th Annual Conference on Protein Structure and Function,
Lorne, Australia. Feb 12-16, 1989.
14
14.
Scott NA, Boublik JH, Rivier JE, Brown MR. Neuropeptide Y (NPY) decreases
mean arterial pressure and cardiac output in passively immunized animals. New
York Academy of Science Conference on the Central and Peripheral Significance
of Neuropeptide Y and its related peptides. Baltimore MD, April 2-4, 1990.
15.
Boublik JH, Spicer MA, Rivier JE, Scott NA, Brown MR. Neuropeptide Y:
structure-activity relationships of synthetic analogs. Future Directions in
Cardiovascular Research, September 4-6, 1990.
16.
Martin TD, Martin SJ, Connolly MW, Scott NA, Gravanis MB. Takayasu's
arteritis: aneurysmal disease without occlusive disease. American College of
Chest Physicians, 1991.
17.
Kern MA, Segal J, Ofili E, Heuser R, Scott NA, Aguirre F, St. Vrain J, Labovitz
A. A new method for quantitating coronary collateral flow in patients during
coronary angioplasty using the doppler guidewire. Circulation 84 (SupplI): II293, 1991.
18.
Hearn JA, Douglas JS, Roubin GS, Ghazzal ZMB, Scott NA, King SB. Late
outcome in patients receiving a balloon-expandable intracoronary stent for acute
closure. Circulation 84 (SupplI): II-589, 1991.
19.
Santoian EC, Gravanis MB, Anderberg K, Scott NA, Karas SP, Schneider JE,
King SB. Use of a porous infusion balloon in swine coronary arteries: low
pressure minimizes arterial damage. Circulation 84 (SupplI): II-591, 1991.
20.
Scott NA, Weintraub WS, Carlin SF, Tao X, Hearn JA, Lembo NJ, Douglas JS,
King SB. Acute closure during PTCA: Improved management with intracoronary
stents, laser balloons and prolonged inflation. JACC 19: 93A, 1992.
21.
Scott NA, Kelsey SF, Dingiloglu H, Detre K, Desvigne-Nickens P, Cowley MJ,
King SB. PTCA in African-American patients: A review of the NHLBI registry.
JACC 19: 139A, 1992.
22.
Schneider JE, Gravanis MB, Santoian EC, Scott NA, Anderberg K, Cipolla G,
King SB. Repeat balloon injury markedly increases smooth muscle cell
proliferation and alters the pattern of intimal hyperplasia in a swine model of
restenosis. JACC 19: 168A, 1992.
23.
Schneider JE, Santoian EC, Gravanis MB, Cipolla GD, Tarazona N, Scott NA,
King SB. Timing of repeat balloon injury influences intimal hyperplasia in a
swine model of coronary restenosis. Society for Cardiac Angiography, 1992.
24.
Santoian EC, Gravanis MB, Karas SP, Anderberg K, Scott NA, Schneider JE,
King SB. Porous balloon infusion of high dose heparin does not inhibit intimal
15
hyperplasia in a normolipemic swine balloon injury model. Society for Cardiac
Angiography, 1992.
25.
Santoian EC, Gravanis MB, Karas SP, Schneider JE, Anderberg KA, Scott NA,
Cipolla G, King SB. Sequence of the reparative phenomena and development of
smooth muscle proliferation following coronary angioplasty in a swine restenosis
model. Clin Res 40:364A, 1992.
26.
Nunes GL, King SB, Hanson SR, Sahatjian RA, Scott NA. Hydrogel-coated
PTCA balloon catheter delivery of an antithrombin inhibits platelet-dependent
thrombosis. Circulation 86:II-380,1992.
27.
Nunes GL, Hanson SR, Rowland SM, Juman I, Spaulding R, Robinson KA,
Harker LA, Scott NA. A comparison of the thrombogenicity of stainless steel
and tantalum coronary stents. Circulation 86:II-732, 1992.
28.
Santoian EC, Schneider JE, Karas SP, Cipolla GD, Tarazona N, Scott NA,
Robinson KA, Gravanis MB. Neointimal differences in swine coronary arteries
after single balloon injury, balloon reinjury or stent injury. Circulation 86:II-801,
1992.
29.
Deychak YA, Thompson MA, Rohrbeck SC, Mukherjee A, Herzog WR,
Lundergan C, Scott N, Segal J. A Doppler guidewire used to assess coronary
flow during directional coronary atherectomy. Circulation 86:I-22, 1992.
30.
Robinson KA, Scott NA, Nunes GM. Comparison of stainless steel and tantalum
as biomaterials for vascular stents. Scanning Microscopy 1992 Meeting, May 914, Chicago IL.
31.
Nunes GL, Hanson SR, King SB III, Sahatjian RA, Barry JJ, Scott NA. Local
heparin delivery with a hydrogel-coated PTCA balloon catheter inhibits plateletdependent thrombosis. J Am Coll Cardiol 21 (2): 117A, 1993.
32.
Ghazzal ZMB, Hinohara T, Scott NA, Baim DS, Safian RD, Fishman N, King SB
III. Directional coronary atherectomy in patients with recent myocardial
infarction: A NACI Registry report. J Am Coll Cardiol 21 (2): 32A, 1993.
33.
Nunes GL, Scott NA, Harker LA, King SB III, Hanson SR. Local delivery of an
antithrombin inhibits platelet-dependent thrombosis. Soc for Cardiac
Angiography and Interevntions, 1993.
34.
Scott NA, Candal FJ, Robinson KA, Ades EW. Seeding of intracoronary stents
with human endothelial cells. Circulation 88 (Suppl I): I-150, 1993.
16
35.
Scott NA, Capers Q, Weintraub WS, Liberman HA, Morris DC, Douglas JS Jr.,
In hospital and long term outcome of PTCA in African-American women and
men. Circulation 88 (Suppl I): I-449, 1993.
36.
Scott NA, Weintraub WS, Liberman HA, Morris DC, Douglas JS Jr., King SB III.
Outcome after acute closure syndrome following coronary angioplasty.
Circulation 88 (Suppl I): I-299, 1993.
37.
Wilcox JN, Scott NA, Lumsden AB, Subramanian RR, Rodriguez JC, Kelly AB.
Onset of cell proliferation and growth factor expression after clinical angioplasty
of primate vascular lesions. Circulation 88 (Suppl I): I-469, 1993.
38.
Waksman R, Scott NA, Douglas JS Jr, Mays R, Yee-Petersen J, King SB III.
Distal embolization is common after directional atherectomy in coronary arteries
and vein grafts. Circulation 88 (Suppl I): I-299, 1993.
39.
Robinson KA, Candal FJ, Scott NA, Ades EW. Seeding of vascular grafts with
an immortalized human dermal microvascular endothelial cell line. American
College of Angiology Annual Meeting, October 1993, Orlando FL.
40.
Thomas CN, Barry JJ, King SB III, Scott NA. Local delivery of heparin with a
PTCA infusion balloon inhibits platelet-dependent thrombosis. J Am Coll
Cardiol 4A, 1994.
41.
Thomas CN, Robinson KA, Cipolla GD, Jones M, King SB III, Scott NA. Invivo local delivery of heparin to coronary arteries with a microporous infusion
catheter. J Am Coll Cardiol 484A, 1994.
42.
Capers Q IV, Thomas CN, Weintraub WS, King SB III, Douglas JS Jr, Scott NA.
Emergent stent placement: worse outcome in the patients with a recent
myocardial infarction. J Am Coll Cardiol 71A, 1994.
43.
Thomas CN, Capers Q IV, Frerichs FA, Petersen J, Douglas JS Jr, Ghazzal ZMB,
King SB III, Scott NA. Clinical outcome in stenting following acute versus
threatened closure. Clinical Research 1994.
44.
Hanson SR, Wilcox JN, Kelly AB, Lumsden AB, Scott NA, Harker LA.
Thrombin mediation of arterial smooth muscle cell proliferation after mechanical
injury in non-human primates. Blood 80(suppl 1): 166A, 1992.
45.
Waksman R, Ghazzal ZMB, Fernandez A, Scott NA, Douglas JS Jr. Efficacy and
Safety of using perfusion dilatation catheter as initial balloon in coronary
angioplasty. Washington D.C. Feb 24-27, 1994.
17
46.
Scott NA, Ross CE, Subramanian RR, Martin F, Simonet L, Wilcox JN.
Characterization of the Cellular Response to Coronary Injury. Circulation 90
(Suppl I): I-392, 1994.
47.
Robinson KA, Waksman R, Thomas C, Sigman SR, Cipolla GD, Rowland S,
Jones M, Scott NA, King SB III. Transfer of Microparticles to Balloon-injured
Swine Coronary Arteries Using the Microporous Infusion Catheter. JACC. 5A,
February 1994.
48.
Wilcox JN, Scott NA, Subramanian RR, Ross CE, Adams-Burton CR,
Stoltenborg JK, Corjay MH. A Potential Role for BTG1, an Anti-Proliferative
Gene, in the Control of Cell Proliferation After Angioplasty of Porcine Coronary
Arteries. Circulation 92 (Suppl I): I-34, 1995.
49.
Scott NA, Ross CE, Wilcox JN. The Relationship Between Cellular Proliferation
and Thrombus Formation After Balloon Oversterch Angioplasty of Porcine
Coronary Arteries. Circulation 92 (Suppl I): I-111, 1995.
50.
Weintraub WS, Ghazzal ZMB, Scott NA, Douglas Jr JS, Benard J, Mauldin P,
Becker E, King SB III. Declining Resource Utilization in Interventional
Cardiology. JACC. 81A, February 1995.
51.
Waksman R, Rodriguez JA, Robinson KA, Scott NA, Crocker IR, Ross CE,
Wilcox JN. Intracoronary Radiation Affects Restenosis in the Swine Model by
Reduction of Cell Proliferation and Favorable Remodeling. Circulation 94 (Suppl
I): I-108, 1996.
52.
Waksman R, Shen Y, Ghazzal Z, Scott NA, Douglas JS Jr, King SB III. Optimal
Balloon Inflation Pressures for Stent Deployment and Correlates of Stent
Thrombosis and In-Stent Restenosis. Circulation 94 (Suppl I): I-258, 1996.
53.
Oshinski JN, Dixon WT, Trudeau J, Hofland L, Scott NA, Pettigrew RI.
Navigator Echo Gating Improves Coronary MRA. Circulation 94 (Suppl I): I417, 1996.
54.
Waksman R, Robinson KA, Scott NA, Crocker IR, King SP III, Ross CE, Cipolla
GD, Wilcox JN. Endovascular Radiation Reduces Vascular Lesion Formation
After Balloon Injury of Pig Coronary Arteries by Inhibiting Cell Proliferation.
JACC. 14A, February 1996.
55.
Okamoto E, Couse TL, Goodman RB, Scott NA, Wilcox JN. Perivascular
Inflammation after Balloon Angioplasty of Porcine Coronary Arteries.
Circulation 100 (18 Suppl 2): 607, 2000.
18
56.
Scott NA, Powers N, Shih LB, Harris S, Peters D, Segal J. Local Delivery of
Paclitaxel with an Iontophoretic Catheter Prevents Neointimal Proliferation after
Coronary Injury and Stent Placement. Amer J Cardiol 92 (6 Suppl 1), 2003.
57.
Scott NA, Powers N, Shih LB, Harris S, Peters D, Segal J. Local Delivery of E2F
Decoy with an Iontophoretic Catheter Prevents Neointimal Proliferation after
Stent Placement. Amer J Cardiol 92 (6 Suppl 1): 95L, 2003.
58.
Segal J, Peters D, Shen N, Shih LB, Scott NA. A New Iontophoretic Catheter for
Treatment of Hemodialysis Graft Stenosis. Amer J Cardiol 92 (6 Suppl 1), 2003.
59.
Whitbourn RJ, Turovskiy R, Liu J, Pandya S, Scott NA. First in Man Clinical
Experience with the CardioMind 0.014” Sparrow™ Drug Eluting Coronary Stent
System. Amer J Cardiol 102 (Issue 8), October 2008.
60.
Scott NA, Harris S, Burkoth T, Powers N, Segal J. Intracoronary Paclitaxel
Delivery with a Novel Mesh Catheter. Amer J Cardiol 2009 (in press).
19